CP-320626 is a potent inhibitor, synergistic with glucose, of human liver glycogen phosphorylase a (LGPa). It is a possible target for type 2 diabetes therapy. CP320626 is also a potent inhibitor of human muscle GPa. References: Ma D, Wang J, Zhao Y, Lee WN, Xiao J, Go VL, Wang Q, Recker RR, Xiao GG. Inhibition of glycogen phosphorylation induces changes in cellular proteome and signaling pathways in MIA pancreatic cancer cells. Pancreas. 2012 Apr;41(3):397-408. doi: 10.1097/MPA.0b013e318236f022. PubMed PMID: 22158071; PubMed Central PMCID: PMC3306546.

纯度：≥98%

CAS：186430-23-9